Navigation Links
Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results

Company resumes commercial operations with first product sales since 2005

SEATTLE, May 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported financial results for the quarter ended March 31, 2008. Total revenues for the quarter were $3.4 million compared to $20,000 for the first quarter of 2007. Gross product sales of Zevalin(R) (Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.

Total operating expenses increased to $28.4 million for the quarter ended March 31, 2008 compared to $23.6 million for the same period in 2007 mainly as a result of increased expenses related to the creation of commercial infrastructure to support Zevalin and fees associated with capital structure advisory services. Net loss attributable to common shareholders for the quarter ended March 31, 2008, which includes a one-time inducement payment of $16.2 million to convert preferred shares into common shares, totaled $54.6 million ($0.77 per share) compared to $28.7 million ($0.76 per share) for the comparable period in 2007. The increase in net loss attributable to common shareholders was also due, in part, to an increase in interest expense and make-whole interest payments related to the 9% convertible senior notes and the loss recorded on the exchange of the 5.75% convertible senior subordinated and subordinated notes in 2008. This was offset by a gain on the derivative liability related to conversions of the 9% convertible senior notes. We also had a foreign exchange loss for the quarter ended March 31, 2008 compared to a gain for the same period in 2007.

The Company had approximately $15.3 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of March 31, 2008. This does not include $6.2 million in restricted cash held in escrow and net proceeds, before fees and expenses, of approximately $22.9 million from the issuance on April 30, 2008 of preferred stock, convertible notes, and warrants. The Company also expects to receive an additional $5 million in gross proceeds from an additional sale of securities to the purchaser of the Series E preferred stock and 13.5% convertible senior notes prior to July 4, 2008, provided adequate shares are available for issuance of such securities at that time.

"In the second quarter we expect to see the positive financial impact of our strategy to focus resources on our late-stage development products and growing Zevalin sales. With our commercial team now in place to support Zevalin, we expect revenues to continue to increase over the next few quarters," said James A. Bianco, M.D., President and CEO of CTI. "In addition, over the last two quarters, we have been successful in cleaning up our balance sheet, retiring or exchanging approximately 74 percent of current debt and preferred securities. With the majority of the investments in OPAXIO and pixantrone behind us we look forward to the review of the MAA for OPAXIO and to final results of the pixantrone pivotal trial."

Recent Highlights

o Announced that the Company selected and received a positive opinion

from the European Medicines Agency (EMEA) on the new brand name

OPAXIO(TM) (paclitaxel poliglumex), which replaces the name XYOTAX(TM)

o Announced that the EMEA accepted for review CTI's Marketing

Authorization Application (MAA) for OPAXIO for first-line treatment of

patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern

Cooperative Oncology Group) performance status 2 (PS2)

o Announced completion of enrollment in the phase III EXTEND (PIX301)

clinical trial of pixantrone (BBR 2778) for patients with relapsed

diffuse large B-cell non-Hodgkin's lymphoma (NHL)

o Announced the appointment of Craig W. Philips, most recently Vice

President and General Manager of Bayer Healthcare Oncology, as

president of CTI with direct responsibilities for development and

commercial operations, effective August 1, 2008

o Restructured, or retired more than $66 million of current convertible

debt and preferred securities while raising over $50 million in gross

proceeds during the past two quarters

Conference Call Information

On Thursday, May 8, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ: CTIC and MTA: CTIC) management team will host a quarterly conference call to discuss the company's 2008 first quarter achievements and financial results.

Conference Call Numbers

Thursday, May 8

8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time

1-877-835-3295 (US Participants)

1-303-262-2137 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:

1-800-405-2236 (US Participants)

1-303-590-3000 (International)

Passcode: 11114025#

Live audio webcast at will be archived for post listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin, reducing net operating expenses in 2008, the closing of an additional financing prior to July 4, 2008, the availability of adequate shares for future financings, and the development of OPAXIO, pixantrone, and brostallicin, which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO, pixantrone, and brostallicin in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, OPAXIO, pixantrone, and brostallicin, the Company's ability to continue to raise capital as needed to fund its operations, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200


Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434


Three Months Ended

March 31,

2008 2007


Product sales $3,374 $-

License and contract revenue 20 20

Total revenues 3,394 20

Operating expenses:

Cost of product sold 890 -

Research and development 15,855 15,286

Selling, general and administrative 11,174 8,130

Amortization of purchased intangibles 397 207

Acquired in-process research and

development 36 -

Total operating expenses 28,352 23,623

Loss from operations (24,958) (23,603)

Other income (expense):

Investment and other income 260 703

Interest expense (12,929) (3,916)

Foreign exchange gain (loss) (2,237) 447

Make-whole interest expense (7,781) (2,310)

Gain on derivative liabilities 11,744 2,708

Loss on exchange of convertible notes (2,295) -

Settlement expense - (143)

Net loss before minority interest (38,196) (26,114)

Minority interest in net loss of subsidiary 32 -

Net loss (38,164) (26,114)

Preferred stock beneficial

conversion feature - (2,594)

Preferred stock dividends (242) (31)

Deemed dividends on conversion of

preferred stock (16,198) -

Net loss attributable to common

shareholders $(54,604) $(28,739)

Basic and diluted net loss per common share $(0.77) $(0.76)

Shares used in calculation of basic

and diluted net loss per common share 71,074 37,588

Balance Sheet Data: (amounts in thousands)

March 31, December 31,

2008 2007

Cash and cash equivalents, securities

available-for-sale (unaudited)

and interest receivable $15,341 $18,392

Restricted cash 6,165 -

Working capital (20,395) (30,909)

Total assets 78,636 73,513

Convertible debt 145,530 137,396

Accumulated deficit (1,164,017) (1,109,413)

Shareholders' deficit (124,100) (134,125)

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
5. Profarmas Gross Revenues Reached R$ 702.6 Million in the 1st Quarter 2008, a 26.5% Growth Over the Same Period Last Year
6. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. MEDRAD(R) Revenues Grow 10 Percent in 2007
9. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
10. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
11. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
Post Your Comments:
(Date:11/30/2015)... ... December 01, 2015 , ... The Turks & Caicos Islands ... the leading digital news sites highlighting Caribbean destinations, has published five reasons to visit ... of North America shivers under chilly grey skies or worse, it's typically a balmy ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... nation’s leading networking organization exclusively for professional women, boasting more than 850,000 members and ...
(Date:11/30/2015)... ... November 30, 2015 , ... 1Heart Caregiver Services’ Executive ... Federation of Philippine American Chambers of Commerce held from November 6-8, 2015 at ... Caregiver Services, as an active delegate from the Philippine American Chamber of Commerce ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... extremely stressful. At the VA Maryland Health Care System, the Caregiver Support ... patients. “Caregivers have a difficult job. Seventy-four percent report that their role ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover ... , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance Administration ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , 2,917 ...
(Date:11/30/2015)... INDIANAPOLIS , Nov. 30, 2015  PTS Diagnostics, ... as CardioChek ® analyzers, A1CNow ® systems, ... of a family of patents that will propel the ... and Europe . The ... cameras, such as those on smartphones and tablets, and ...
(Date:11/30/2015)... -- Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi , ... 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December 3, ... --> --> This will be ... ask the company questions in real-time - both in the ...
Breaking Medicine Technology: